spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  mixed dyslipidemia 

 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Apr 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2016
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Jul 2016
Mylan Launches Generic Fenoglide(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 May 2014
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Sep 2013
Teva Announces Exclusive Launch of Generic NIASPAN(R) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 31 May 2012
New Data Showed LIVALO(R) (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 25 Nov 2011
Amarin Announces Resignation of David Feigal from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2011
Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Nov 2010
Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2010
Amarin Corporation Announces Senior Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2010
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2010
Abbott's SIMCOR(R) (niacin extended-release / simvastatin) Receives FDA Approval for New Dosage Strengths
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 2 Dec 2009
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 13 Oct 2009
Amarin Announces Changes to Its Board and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2009
FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 8 Jun 2009
Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2009
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Dec 2008
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2008
Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Jul 2008
TREDAPTIVE(TM) (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 20 Jun 2008
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2008
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Apr 2008
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Feb 2008
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 9 Nov 2007
CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
Biopharmaceuticals FDA Cardiology
 HSMN NewsFeed - 7 Nov 2007
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Nov 2007
Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2007
Merck's Investigational Lipid-Modifier, CORDAPTIVE(TM) (ER niacin/laropiprant), Positively Affected Key Lipid Parameters With Less Flushing, In Data from Phase III Study
Biopharmaceuticals Drug Delivery Cardiology
 HSMN NewsFeed - 31 Aug 2007
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Biopharmaceuticals
 HSMN NewsFeed - 23 Jun 2007
New Study Demonstrates Colesevelam HCl Lowers Both A1C and LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 20 Apr 2007
Abbott Submits New Drug Application for Combination Niaspan(R)/Simvastatin Tablet
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2007
Sciele Begins to Enroll Patients in a Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Apr 2007
Abbott Announces FDA Approval of a New Coated Niaspan Tablet
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Jul 2006
Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Jul 2006
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 39

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 39 additional stories matching:
mixed dyslipidemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.